PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection

Document Type

Conference Proceeding

Publication Date

7-1-2024

Publication Title

J Thorac Oncol

Keywords

adult, African American, aged, Caucasian, Charlson Comorbidity Index, chronic obstructive lung disease, conference abstract, controlled study, coronavirus disease 2019, diagnosis, female, human, incidence, lung cancer, major clinical study, male, never smoker, non small cell lung cancer, overall survival, progression free survival, retrospective study, second-line treatment, smoking, special situation for pharmacovigilance, surgery, very elderly

Abstract

Background: The incidence of lung cancer (LC) has been described to be higher among patients diagnosed with COVID-19 (Lemos AEG et al). It is suggested that this is due to more imaging being performed in the setting of COVID-19 infection. In this analysis, we evaluated the outcomes of patients who were diagnosed with LC after COVID-19. Methods: This is a retrospective study including patients who were diagnosed with small cell (SCLC) and non-small cell (NSCLC) lung cancer within 6 months of their diagnosis with COVID-19 infection. Primary endpoint was overall survival (OS) defined as time from LC diagnosis to death. Secondary endpoint was progression-free survival (PFS) defined as time from LC diagnosis to progression or death. Results: A total of 86 patients were included in our analysis. Of those, 66.3%, 17.4%, 16.3% were diagnosed with non-squamous NSLCC (NSQ-NSCLC), squamous NSCLC (SQ-NSCLC), and SCLC, respectively. The mean age of patients was 70 years, 62% females and 38% males, 65% Caucasians and 23% African Americans. The mean Charlson Comorbidity Index score was 3.1 (SD of 2.2). 70.6% of patients were diagnosed with COPD. The mean smoking pack years was 42.7 years (SD 28.4) and 16.3% of patients were never smokers. Of patients with NSQ-NSCLC: 38%, 29.8%, and 31.6% had stage I-II, III, IV, respectively. Of patients with SQ-NSCLC, they were split evenly among all stages. Of patients with SCLC, most were stage IV (71.4%). Treatments received included surgery (33.7%), radiation (26.7%), chemotherapy (41.9%), immunotherapy (23.3%), and targeted therapy (4.7%). Outcomes are illustrated in Table 1. Twelve patients (14%) received a second line treatment. Conclusions: In this retrospective analysis, the percentage of patients diagnosed with early-stage NSCLC was higher than the pre-COVID incidence rate. Patients were able to receive standard of care treatments and the outcomes were consistent with their anticipated stage-adjusted survival. [Formula presented]

PubMed ID

Not assigned.

Volume

19

First Page

e49

Find It @ Sladen

Share

COinS